Ocugen, Inc. 8K

Ocugen, Inc. entered into a binding term sheet to license its OCU400 gene therapy for Retinitis Pigmentosa in the MENA region to Roots Pharmaceutical and partner Al-Dhow, with milestones, royalties, and supply obligations pending a definitive agreement expected within 90 days.

On July 13, 2026, Ocugen, Inc. announced it has signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding to negotiate and enter into an exclusive license and related supply agreement granting Roots rights to OCU400, Ocugen’s modifier gene therapy for Retinitis Pigmentosa, in the Middle East and North Africa region, under which Ocugen expects up to $4 million in upfront and near-term development milestone payments, up to $255 million in cumulative sales milestone payments, a 22% royalty on net sales, and will manufacture commercial supply of OCU400, with execution of a definitive agreement anticipated within 90 days and OCU400 continuing in Phase 3 development toward a planned BLA submission following an expected topline readout in Q1 2027.

Filing Facts

CIK

1372299

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-082897

Alert Tier

6